ipoprotein (a) as a risk factor for restenosis in patients with aortoiliac disease undergoing endovascular management

Not Applicable

• Conditions: Aortoiliac occlusive disease; Peripheral arterial disease; Stenosis; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12621000713897
• Lead Sponsor: Royal Perth Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-08
• Last Update Posted: 5 July 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Patients greater than or equal to 18 years of age
2. The participant has provided written informed consent
3. Evidence of TASC B, C or D lesions (TASC II classification)
4. Patients undergoing endovascular therapy for aortoiliac occlusive disease

Exclusion Criteria

1. Patients less than 18 years of age
2. Pregnant women or women of childbearing potential who are not using an effective method of contraception
3. Uncontrolled hypertension
4. TASC A lesion
5. Patients requiring open procedure
6. Extensive common femoral artery disease or multiple groin procedures
7. Contraindication to antiplatelet use
8. Occluded superficial and profunda femoral arteries
9. Noncompliance with protocol requirements
10.Previous or planned surgical or interventional procedure within 14 days before or 30 days after the index procedure

Study & Design

• Study Type: Interventional
• Study Design: Not specified